Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on RECORDATI SPA. We currently have 0 research reports from 0 professional analysts.
|11Apr17 13:11||GNW||RECORDATI: SHAREHOLDERS APPROVE THE 2016 ACCOUNTS. DIVIDEND € 0.70 PER SHARE (+16.7% vs 2015)|
|01Mar17 11:39||GNW||RECORDATI: BOARD APPROVES THE 2016 ACCOUNTS. SALES € 1,153.9 MILLION (+10.1%), OPERATING INCOME € 327.4 MILLION (+17.6%) AND NET INCOME € 237.4 MILLION (+19.4%). 2016 DIVIDEND € 0.70 (+16.7%)|
|27Feb17 08:01||GNW||RECORDATI SIGNS AN EXCLUSIVE LICENSE AGREEMENT WITH THE MEYER HOSPITAL IN FLORENCE|
|09Feb17 11:05||GNW||RECORDATI: PRELIMINARY 2016 RESULTS CONFIRM CONTINUED GROWTH OF REVENUES AND PROFITABILITY. NEW THREE YEAR BUSINESS PLAN PRESENTED|
|01Feb17 08:05||GNW||RECORDATI TO MEET WITH THE FINANCIAL COMMUNITY AND SPECIALIZED PRESS IN MILAN|
|27Jan17 10:59||GNW||RECORDATI ANNOUNCES MARKETING APPROVAL FOR CYSTADROPS®|
|02Aug16 07:09||GNW||RECORDATI AND RICHTER SIGNED A LICENSE AGREEMENT FOR MARKETING CARIPRAZINE IN WESTERN EUROPE|
Frequency of research reports
Research reports on
20 Apr 17
Although the last two months have seen a broadly neutral performance from the UK healthcare sector compared to a significantly more volatile 6 months prior, we continue to expect macro-events and increased geo-political risk to result in an overall neutral performance from the sector over the next period. However, company specific news is likely to drive a strong outperformance from selected mid-market companies. We retain our neutral sector stance whilst highlighting those we expect to outperform.
N+1 Singer - Small-cap quantitative research - Growth style screen revamp and 10 focus stocks
06 Apr 17
We have reviewed the performance of our consistent growth screen since the previous refresh on 27 September 2016 and revamped the selection parameters to focus more on forecast sales and EPS growth going forward. In the period under review the consistent growth style screen outperformed the small-cap benchmark by c. 6% and underperformed the microcap index by a similar amount. Interestingly, although growth doesn’t always seem to be defensive as might be expected, however it appears right to buy growth on dips caused by or coincident with wider market volatility. In the new forecast growth screen we take a close look at 10 focus stocks. We will monitor performance and refresh it in three to four months time.
N+1 Singer - Morning Song 24-04-2017
24 Apr 17
First Derivatives (FDP LN) FY slightly ahead as strong trading momentum continues | Goals Soccer Centres (GOAL LN) A potentially exciting corporate development | mporium Group (MPM LN) 2016 results: course set for exciting 2017 | Vectura Group (VEC LN) VR315 risk outweighs longer-term potential
24 Apr 17
Lok’nStore* (LOK): Growth supported by a strong balance sheet (CORP) | Mortice* (MORT): UK acquisition (CORP) | Avacta* (AVCT): Another milestone – 1st non-therapeutics licence (CORP) | Petra Diamonds (PDF): Trading update and Q3 results (BUY) | Nasstar* (NASA): Growth and margin focus (CORP)
N+1 Singer - Vectura Group - VR315 risk outweighs longer-term potential
24 Apr 17
Following a review of product-level forecasts, we have reduced FY2017-18e revenue forecasts by 6.6% & 10.9% respectively. Following Mylan’s generic Advair® setback, we have also downgraded the likelihood of success for VR315 in the US. Although we remain impressed by the depth of Vectura’s pipeline, the potential valuation upside does not currently outweigh the risk of VR315 non-approval or delayed approval. We downgrade to Sell ahead of the 10th May GDUFA date with a TP of 131p (from 202p).